M. Veerkamp

Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study

J. Hendriks, P. Demacker, A. Stalenhoef, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia.

P. Demacker, A. Stalenhoef, S. Bredie, 2000, Atherosclerosis.

Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD.

M. den Heijer, L. V. van Tits, A. Stalenhoef, 2005, Atherosclerosis.

Role of Insulin Resistance in Familial Combined Hyperlipidemia

A. Stalenhoef, J. de Graaf, M. Veerkamp, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

A. Stalenhoef, J. de Graaf, M. Veerkamp, 2002, Journal of the Royal Society of Medicine.

Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study

J. Hendriks, P. Demacker, A. Stalenhoef, 2004, Circulation.

5-Year Follow-Up Study Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a

J. Hendriks, J. Graaf, P. Demacker, 2017 .

Familial Combined Hyperlipidemia: metabolic features and new diagnostic criteria.

M. Veerkamp, 2004 .

Plasma homocysteine in subjects with familial combined hyperlipidemia.

H. Blom, M. den Heijer, A. Stalenhoef, 2003, Atherosclerosis.